Mhairi Copland, MBChB, PhD, University of Glasgow, Glasgow, UK, discusses treatment options for blast phase CML, pointing out that TKI therapy alone with ponatinib has a 3-year survival rate of about 9%. Ponatinib combined with chemotherapy has shown promise in achieving a second chronic phase or cytogenetic response. Further studies are ongoing to determine the most effective combination therapy.